Schwedt TJ (2014) Chronic migraine. BMJ 348:g1416

Article  PubMed  Google Scholar 

Headache Classification Committee of the International Headache Society (IHS) (2018) The International classification of Headache disorders, 3rd edition. Cephalalgia 38(1):1–211

Buse DC, Manack A, Serrano D, Turkel C, Lipton RB (2010) Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 81(4):428–432

Article  CAS  PubMed  Google Scholar 

Lanteri-Minet M (2014) Economic burden and costs of chronic migraine. Curr Pain Headache Rep 18(1):385

Article  PubMed  Google Scholar 

Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53(4):644–655

Article  PubMed  Google Scholar 

Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37(5):470–485

Article  PubMed  Google Scholar 

Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35(6):478–488

Article  PubMed  Google Scholar 

Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A et al (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 31(3):301–315

Article  CAS  PubMed  Google Scholar 

Bigal ME, Lipton RB (2011) Migraine chronification. Curr Neurol Neurosci Rep 11(2):139–148

Article  PubMed  Google Scholar 

Moriarty M, Mallick-Searle T (2016) Diagnosis and treatment for chronic migraine. Nurse Pract 41(6):18–32

Article  PubMed  PubMed Central  Google Scholar 

Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14(6):338–350

Article  CAS  PubMed  Google Scholar 

Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442–1454

Article  PubMed  Google Scholar 

Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of Galcanezumab for the Prevention of episodic migraine: the EVOLVE-1 Randomized Clinical Trial. JAMA Neurol 75(9):1080–1088

Article  PubMed  PubMed Central  Google Scholar 

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211–e21

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pozo-Rosich P, Detke HC, Wang SF, Dolezil D, Li LQ, Aurora SK, Reuter U (2022) Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin 38(5):731–742

Article  CAS  PubMed  Google Scholar 

Dodick DW, Turkel CC, DeGryse RE, Diener HC, Lipton RB, Aurora SK et al (2015) Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. J Pain 16(2):164–175

Article  PubMed  Google Scholar 

Leonardi M, Raggi A (2019) A narrative review on the burden of migraine: when the burden is the impact on people’s life. J Headache Pain 20(1):41

Article  PubMed  PubMed Central  Google Scholar 

Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ et al (2012) Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 13(5):361–378

Article  CAS  PubMed  PubMed Central  Google Scholar 

Messali A, Sanderson JC, Blumenfeld AM, Goadsby PJ, Buse DC, Varon SF et al (2016) Direct and indirect costs of chronic and episodic migraine in the United States: a web-based survey. Headache 56(2):306–322

Article  PubMed  Google Scholar 

Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A, Lipton RB (2016) Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study. Mayo Clin Proc

Goadsby PJ, Evers S (2020) International classification of Headache disorders - ICHD-4 alpha. Cephalalgia 40(9):887–888

Article  PubMed  Google Scholar 

Jedynak J, Eross E, Gendolla A, Rettiganti M, Stauffer VL (2021) Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials. J Headache Pain 22(1):48

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silberstein SD, Stauffer VL, Day KA, Lipsius S, Wilson MC (2019) Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain 20(1):75

Article  CAS  PubMed  PubMed Central  Google Scholar 

Headache Classification Committee of the International Headache S. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia (2013);33(9):629–808

Stokes M, Becker WJ, Lipton RB, Sullivan SD, Wilcox TK, Wells L et al (2011) Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache 51(7):1058–1077

Article  PubMed  Google Scholar 

Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, Lipton R (2012) Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache 52(1):3–17

Article  PubMed  Google Scholar 

Davies P (2012) Medication overuse headache: a silent pandemic. Pain 153(1):7–8

Article  PubMed  Google Scholar 

Shao Q, Rascati KL, Barner JC, Lawson KA, Sonawane KB, Rousseau JF (2022) Healthcare utilization and costs among patients with chronic migraine, episodic migraine, and tension-type headache enrolled in commercial insurance plans. Headache 62(2):141–158

Article  PubMed  Google Scholar 

Negro A, Martelletti P (2019) Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies. Expert Rev Neurother 19(8):769–776

Article  CAS  PubMed  Google Scholar 

Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G et al (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22(1):35

Article  CAS  PubMed  PubMed Central  Google Scholar 

Altamura C, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C et al (2022) Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience. J Neurol 269(11):5848–5857

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schoenen J, Timmermans G, Nonis R, Manise M, Fumal A, Gerard P (2021) Erenumab for Migraine Prevention in a 1-Year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes. Front Neurol 12:805334

Article  PubMed  PubMed Central  Google Scholar 

Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M et al (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21(1):84

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ornello R, Casalena